None Trending Topics New drugs July 11, 2025 – finerenone (Kerendia) Bayer; non-steroidal mineralocorticoid receptor antagonist (MRA); first MRA FDA-approved for heart failure (HF) with left...

Plozasiran, by Arrowhead, is a first-in-class RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3), thereby reducing circulating triglycerides (TG). It...

publications High Cost Therapy Profile: November 2024 Zenocutuzumab Intravenous (IV) Oncology Proposed indications Pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC)...

Merck submitted clesrovimab to the FDA for respiratory syncytial virus (RSV) disease prevention in infants during their first RSV season. If approved, clesrovimab will be the third monoclonal...